XYL

Xylem Inc. Reports 26% Revenue Growth in Q2 2024

Xylem Inc. has reported its second-quarter 2024 results, revealing a 26% increase in revenue to reach $2.2 billion. This impressive growth includes a 9% organic increase. Earnings per share also saw a substantial increase, rising by 78% on a reported basis and 11% on an adjusted basis to $0.80 and $1.09, respectively.

The company has raised its full-year revenue guidance to $8.55 billion, representing approximately a 16% increase on a reported basis and a 5% to 6% increase organically. This adjustment marks an improvement from the previous guidance of 15% to 16% on a reported basis and 4% to 6% organically.

Xylem's net income for the second quarter was $194 million, or $0.80 per share, with a net income margin increase of 360 basis points to 8.9%. Adjusted net income, which excludes certain impacts, was $266 million, or $1.09 per share.

The company's second-quarter adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin was 20.8%, reflecting a year-over-year increase of 170 basis points.

Looking ahead, Xylem now expects its full-year 2024 adjusted EBITDA margin to be approximately 20.5%, up from the previous guidance of 20.0%. This adjustment results in an increased range for adjusted earnings per share, now forecasted to be $4.18 to $4.28, up from the previous range of $4.10 to $4.25.

Xylem has also raised its full-year free cash flow conversion to net income expectation, now anticipating it to be at least 120%, up from the prior guidance of 115%.

For more detailed information, Xylem's second-quarter earnings materials and reconciliations for certain non-GAAP items can be found at www.xylem.com/investors.

The market has reacted to these announcements by moving the company's shares 0.5% to a price of $141.53. For the full picture, make sure to review Xylem's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS